Medicare Coverage Of PET Pharmaceutical Agents Needs Revamp, Industry Says
This article was originally published in The Gray Sheet
A broad range of stakeholders are asking CMS to remove national non-coverage language for newly approved radiopharmaceuticals used in positron emission tomography to allow speedier access to new tools for diagnosing Alzheimer’s and other diseases.
You may also be interested in...
Amgen buys deCode Genetics. CMS opens proposed decision memo on PET radiopharmaceuticals. More news briefs.
CMS opens national coverage analysis for PET tracers to diagnose dementia. HHS Office of Inspector General reports on prosthetics and orthotics payments. More reimbursement news.
Judge rejects Orthofix settlement with feds. ConvaTec purchases catheter-provider 180 Medical. Cook announces new product division. More news briefs.